Status:
COMPLETED
Evaluation of Soybean Peptides Product on Regulation of Blood Pressure Effect in Humans
Lead Sponsor:
Chung Shan Medical University
Conditions:
Hypertension
Eligibility:
All Genders
20-80 years
Phase:
NA
Brief Summary
This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension. Overall, soybean peptide consumption for 8 weeks could successfully reduce mea...
Detailed Description
This is the report to assess supplementation with soybean peptides on blood pressure among people with mild hypertension. Thirty subjects with systolic blood pressure (SBP) between 120 and 159 mm Hg a...
Eligibility Criteria
Inclusion
- Eligible subjects were untreated hypertensive men or women aged between 20 and 80 years old with SBP between 120 and 159 mmHg and/or DBP between 80 and 99 mmHg as measured in a sitting position
Exclusion
- Subjects were excluded if they had a history of major cardiovascular disease or severe liver dysfunction;
- Diastolic blood pressure ≥ 100 mmHg or Systolic blood pressure ≥ 160 mmHg;
- Alcoholic;
- US-controlled diabetics;
- Stoke in past one year;
- Mental diseases or melancholia;
- Pregnancy or breast-feeding a child;
- Renal dysfunction;
- Allergic to Soybean peptides.
Key Trial Info
Start Date :
March 1 2016
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2017
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT03828955
Start Date
March 1 2016
End Date
January 1 2017
Last Update
May 24 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Chung Shan Medical University
Taichung, Taiwan